Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase II Study For Intrahepatic Cholangiocarcinoma With FGFR2 Fusions
Benzinga Newsdesk 4 months ago
News
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —— Fanregratinib holds promise as a new treatment option for pretreated advanced ICC
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —
— Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements —